欧盟委员会批准赛诺菲和西兰Pharma的GLP-1激动剂淋视(Lixisenatide)
2月1日,欧盟委员会宣布,它已批准了Sanofi和西兰的GLP-1激动剂百月(LixIsenatide),适用于2型糖尿病。The drug is a once-daily injection that is particularly useful for controlling after-meal blood glucose levels – early trial results suggested it may be even better than Novo Nordisk’s Victoza specifically for post-meal spikes, but perhaps not in other areas of glucose control. When blood sugar is high, GLP-1 agonists trigger the secretion of insulin, suppress the release of sugar from the liver, and slow the digestion of food. Some people also feel less hungry and eat less. Apart from controlling blood sugar, the two major benefits of the drug are a low risk of hypoglycemia and weight loss, and the main side effect is nausea. Sanofi, which will market Lyxumia, has announced that it will be available in Germany and the UK in the early months of 2013.
赛诺菲已在美国提交了lixisenatide的新药申请(美国的商标名称尚未确定),2月19日FDA接受了该申请。如果获得FDA批准,lixisenatide将成为市场上第4种GLP-1激动剂,紧随其后维多拉,Byetta,Bydureon.Sanofi还在处理单一器件中结合Lixisentatidide和基底胰岛素凉板。它将提供固定剂量的lixisenatide,但让患者调节它们的锰剂量。该组合肯定是患者的麻烦,并且可能有助于改善葡萄糖控制,而不是单独使用的每种治疗。由于患者通常在服用GLP-1激动剂时减肥,因此该组合也可以克服通常用胰岛素治疗所看到的体重增加。不幸的是,Sanofi最近遇到了一个“技术毛刺”,它将延迟其Lixisenatide-Lantus“Fix-Flex”装置从2013年上半年开始阶段3试验。
有许多GLP-1激动剂可用,患者和他们的hcp需要决定哪种药物对他们最有效。对一些人来说,每天一次的Victoza可能更容易开始。每周一次的Bydureon注射让患者不必担心每天服用药物。对其他人来说,餐后血糖飙升可能是一个更大的问题,利西那肽可能是一个不错的选择。更多的选择对患者来说是好消息,这类药物的扩大将使个人更容易优化他们的2型糖尿病管理。锰